Department of Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Am Acad Dermatol. 2015 Nov;73(5):799-801. doi: 10.1016/j.jaad.2015.07.016. Epub 2015 Aug 25.
Vismodegib has been approved for treatment of locally advanced or metastatic basal cell carcinoma (BCC). Its use for postirradiation multiple BCCs has not yet been reported.
We sought to investigate the effectiveness and safety of vismodegib for the treatment of recurrent radiation-induced multiple BCCs.
Patients with recurrent multiple BCCs treated with vismodegib and a history of exposure to radiation treatment were followed up prospectively at a tertiary dermato-oncology clinic during a 19-month period.
Eight patients met the study criteria. Mean duration of vismodegib treatment was 29 weeks (range 2-52), and of follow-up, 34 weeks (range 8-64). Drug tolerability was acceptable in 7 patients, of whom 4 showed a partial response and 3 had stable disease. In 1 patient, vismodegib was discontinued soon after its initiation because of a severe drug-induced eruption.
Small sample size and short follow-up time are limitations.
Vismodegib holds promise for the treatment of the subpopulation of patients with radiation-induced multiple BCCs in whom therapeutic options have so far been limited.
已批准维莫德吉用于治疗局部晚期或转移性基底细胞癌（BCC）。其用于放射性治疗后多发 BCC 的应用尚未见报道。
我们旨在研究维莫德吉治疗放射性治疗后多发 BCC 的疗效和安全性。
在为期 19 个月的时间里，我们在一家三级皮肤肿瘤学诊所对接受维莫德吉治疗并具有放射性治疗史的复发性多发性 BCC 患者进行前瞻性随访。
8 名患者符合研究标准。维莫德吉治疗的平均持续时间为 29 周（范围 2-52 周），随访时间为 34 周（范围 8-64 周）。7 名患者的药物耐受性可接受，其中 4 名患者出现部分缓解，3 名患者病情稳定。1 名患者在开始使用维莫德吉后不久因严重的药物引起的皮疹而停药。
样本量小和随访时间短是其局限性。
对于目前治疗选择有限的放射性治疗后多发 BCC 患者亚群，维莫德吉具有治疗潜力。
